NRx Pharmaceuticals’ (NRXP) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research report sent to investors on Tuesday morning,Benzinga reports. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.50) EPS, Q1 2027 earnings at ($0.30) EPS, Q2 2027 earnings at ($0.15) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at $0.00 EPS, FY2027 earnings at ($0.50) EPS, FY2028 earnings at $0.15 EPS, FY2029 earnings at $0.71 EPS and FY2030 earnings at $1.14 EPS.

Several other equities research analysts also recently weighed in on NRXP. BTIG Research reissued a “buy” rating and issued a $10.00 target price on shares of NRx Pharmaceuticals in a research note on Tuesday, August 18th. Ascendiant Capital Markets lifted their price target on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a “buy” rating in a research note on Monday, April 27th. D. Boral Capital reiterated a “buy” rating and set a $34.00 price target on shares of NRx Pharmaceuticals in a report on Tuesday, May 5th. Wall Street Zen downgraded shares of NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, August 5th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $34.50.

NRx Pharmaceuticals Stock Performance

NASDAQ NRXP opened at $3.62 on Tuesday. The business’s 50 day moving average price is $3.72 and its 200-day moving average price is $3.05. NRx Pharmaceuticals has a fifty-two week low of $1.62 and a fifty-two week high of $5.05. The company has a market cap of $156.75 million, a P/E ratio of -6.58 and a beta of 2.18.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings results on Monday, August 17th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.33). The company had revenue of $1.10 million during the quarter, compared to the consensus estimate of $1.33 million. As a group, equities analysts predict that NRx Pharmaceuticals will post -0.36 EPS for the current year.

Institutional Trading of NRx Pharmaceuticals

A number of large investors have recently made changes to their positions in NRXP. Ethos Financial Group LLC grew its holdings in shares of NRx Pharmaceuticals by 33.6% in the first quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock worth $34,000 after purchasing an additional 4,000 shares during the last quarter. AdvisorShares Investments LLC increased its stake in NRx Pharmaceuticals by 28.2% in the 1st quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company’s stock worth $896,000 after buying an additional 92,463 shares during the period. Anson Funds Management LP lifted its holdings in NRx Pharmaceuticals by 50.3% during the 4th quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock valued at $8,249,000 after buying an additional 1,018,853 shares in the last quarter. State Street Corp lifted its holdings in NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock valued at $236,000 after buying an additional 10,700 shares in the last quarter. Finally, Commonwealth Equity Services LLC purchased a new stake in NRx Pharmaceuticals in the 4th quarter valued at about $994,000. 4.27% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about NRx Pharmaceuticals

Here are the key news stories impacting NRx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating on NRx Pharmaceuticals, maintaining a positive long-term view despite lowering its earnings projections. The firm still expects NRx to become profitable, with projected EPS of $0.15 in 2028, $0.71 in 2029 and $1.14 in 2030. HC Wainwright Reiterates Buy Rating for NRx Pharmaceuticals
• Neutral Sentiment: The estimates imply continued operating losses through 2027, including projected EPS of negative $0.43 in the third quarter of 2026, negative $0.50 in the fourth quarter of 2026 and negative $0.50 for full-year 2027. The analyst’s forecast then turns positive in 2028, suggesting investors must wait for anticipated commercialization or revenue growth.
• Negative Sentiment: HC Wainwright cut its EPS forecasts across nearly every period. Estimates were reduced to negative $0.43 from negative $0.06 for third-quarter 2026, negative $0.50 from negative $0.07 for fourth-quarter 2026, and negative $0.50 from positive $0.67 for full-year 2027. Longer-term estimates were also substantially lowered: 2028 EPS fell to $0.15 from $2.49, 2029 to $0.71 from $4.51, and 2030 to $1.14 from $5.76.
• Negative Sentiment: The revisions reinforce concerns about NRx Pharmaceuticals’ near-term profitability. The company previously reported a quarterly loss of $0.44 per share and revenue below expectations, while the consensus forecast remains a loss for the current year. These factors can weigh on NRXP even with the retained Buy rating, particularly given the stock’s high volatility.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.